Javascript must be enabled to continue!
Parathyroid hormone metabolism and its potential as a uremic toxin
View through CrossRef
Secondary hyperparathyroidism is a universal complication of chronic renal failure. It has been proposed that the markedly elevated levels of immunoreactive parathyroid hormone (i-PTH) in uremia may represent a “uremic toxin” responsible for many of the abnormalities of the uremic state. Plasma i-PTH consists of a mixture of intact hormone, a single-chain polypeptide of 84 amino acids, and smaller molecular weight hormonal fragments from both the carboxy- and amino-terminal portion of the PTH molecule. The hormonal fragments arise from metabolism of intact PTH by peripheral organs as well as from secretion of fragments from the parathyroid glands. The structural requirements for the known biological actions of PTH reside in the amino-terminal portion of the PTH molecule. Carboxy-terminal fragments, biologically inactive at least in terms of adenylate cyclase activation, hypercalcemia, or phosphaturia, depend on the kidney for their removal from plasma, and thus accumulate in the circulation in chronic renal failure. It is unknown at the present time if other biological effects of these carboxy-terminal fragments may contribute to some of the biochemical alterations observed in uremia. The most significant consequence of increased PTH levels in uremia is the development of bone disease characterized by osteitis fibrosa. In addition, it would appear that PTH plays an important role in some of the abnormal electroencephalographic patterns observed in uremia. This may be due to a potential role of PTH in increasing calcium content of brain. Parathyroid hormone also has been implicated as a pathogenetic factor in many other alterations present in uremia, i.e., peripheral neuropathy, carbohydrate intolerance, hyperlipidemia, and other alterations. Unfortunately, outstanding clinical research is lacking in this field and conclusive experimental data are practically nonexistent. Further studies are necessary if one is to accept the concept of PTH being a significant “uremic toxin.”
American Physiological Society
Title: Parathyroid hormone metabolism and its potential as a uremic toxin
Description:
Secondary hyperparathyroidism is a universal complication of chronic renal failure.
It has been proposed that the markedly elevated levels of immunoreactive parathyroid hormone (i-PTH) in uremia may represent a “uremic toxin” responsible for many of the abnormalities of the uremic state.
Plasma i-PTH consists of a mixture of intact hormone, a single-chain polypeptide of 84 amino acids, and smaller molecular weight hormonal fragments from both the carboxy- and amino-terminal portion of the PTH molecule.
The hormonal fragments arise from metabolism of intact PTH by peripheral organs as well as from secretion of fragments from the parathyroid glands.
The structural requirements for the known biological actions of PTH reside in the amino-terminal portion of the PTH molecule.
Carboxy-terminal fragments, biologically inactive at least in terms of adenylate cyclase activation, hypercalcemia, or phosphaturia, depend on the kidney for their removal from plasma, and thus accumulate in the circulation in chronic renal failure.
It is unknown at the present time if other biological effects of these carboxy-terminal fragments may contribute to some of the biochemical alterations observed in uremia.
The most significant consequence of increased PTH levels in uremia is the development of bone disease characterized by osteitis fibrosa.
In addition, it would appear that PTH plays an important role in some of the abnormal electroencephalographic patterns observed in uremia.
This may be due to a potential role of PTH in increasing calcium content of brain.
Parathyroid hormone also has been implicated as a pathogenetic factor in many other alterations present in uremia, i.
e.
, peripheral neuropathy, carbohydrate intolerance, hyperlipidemia, and other alterations.
Unfortunately, outstanding clinical research is lacking in this field and conclusive experimental data are practically nonexistent.
Further studies are necessary if one is to accept the concept of PTH being a significant “uremic toxin.
”.
Related Results
Pseudohypoparathyroidism versus signaling disorder: A case report
Pseudohypoparathyroidism versus signaling disorder: A case report
Pseudohypoparathyroidism is a terminology used to describe a group of metabolic disorders characterized by parathyroid hormone resistance. Patients with pseudohypoparathyroidism ha...
Defects in platelet adhesion and aggregate formation in uremic bleeding disorder can be attributed to factors in plasma.
Defects in platelet adhesion and aggregate formation in uremic bleeding disorder can be attributed to factors in plasma.
Uremia is associated with bleeding diathesis. Platelet adhesion to the subendothelium is inhibited by a factor in uremic plasma that may play a role in the disturbed hemostasis of ...
Primary and Metastatic Parathyroid Malignancies: A Rare or Underdiagnosed Condition?
Primary and Metastatic Parathyroid Malignancies: A Rare or Underdiagnosed Condition?
Objective:
Parathyroid gland malignancies are considered rare. The most common of these tumor types is primary parathyroid carcinoma. Metastatic spread from other...
The Importance of Correlation between Aldosterone and Parathyroid Hormone in Patients with Primary Hyperparathyroidism
The Importance of Correlation between Aldosterone and Parathyroid Hormone in Patients with Primary Hyperparathyroidism
In primary hyperparathyroidism, an increased risk of developing the cardiovascular disease may exist due to increased activity of the renin-angiotensin-aldosterone system. The aim ...
Renal Phosphate Loss in Long-Term Kidney Transplantation
Renal Phosphate Loss in Long-Term Kidney Transplantation
Summary
Background and objectives
Renal phosphate wasting occurs early postkidney transplantation as a result of an accumulation of parathyroid h...
Cross-Expression of Thymic and Parathyroid Hormone Receptors Supports the Hypothesis of a Parathyroid–Thymus Port System
Cross-Expression of Thymic and Parathyroid Hormone Receptors Supports the Hypothesis of a Parathyroid–Thymus Port System
The thymus and parathyroid glands share a common embryological origin from the third pharyngeal pouch, yet their potential morphological and functional interconnections remain insu...
Fluoride Therapy and Parathyroid Hormone Activity in Osteoporosis
Fluoride Therapy and Parathyroid Hormone Activity in Osteoporosis
1. To determine the relationships between parathyroid hormone activity and long-term sodium fluoride therapy in osteoporosis, cytochemical bioassays (for biologically active parath...
The entry of diphtheria toxin into the mammalian cell cytoplasm: evidence for lysosomal involvement.
The entry of diphtheria toxin into the mammalian cell cytoplasm: evidence for lysosomal involvement.
Lysosomotropic amines, such as ammonium chloride, are known to protect cells from the cytotoxic effects of diphtheria toxin. These drugs are believed to inhibit the transport of th...

